Cargando…
Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models
SIMPLE SUMMARY: Adoptively transferred T cells expressing recombinant chimeric antigen receptors (CAR T cells) have been approved for the therapy of hematological malignancies of the B cell lineage. However, CAR T cell therapy for patients with solid tumors so far has shown limited benefits. Correla...
Autores principales: | Csaplár, Marianna, Szöllősi, János, Gottschalk, Stephen, Vereb, György, Szöőr, Árpád |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428348/ https://www.ncbi.nlm.nih.gov/pubmed/34503109 http://dx.doi.org/10.3390/cancers13174301 |
Ejemplares similares
-
CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells
por: Mezősi-Csaplár, Marianna, et al.
Publicado: (2023) -
CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation
por: Barden, Markus, et al.
Publicado: (2023) -
A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts
por: Tóth, Gábor, et al.
Publicado: (2020) -
In vitro, in vivo and microscopic analysis of tumor immunotherapy using combination of two antibodies against the same ErbB2 target
por: Toth, Gabor, et al.
Publicado: (2014) -
The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity
por: Tóth, Gábor, et al.
Publicado: (2016)